Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts W/Chronic Myeloid Leukemia

Launched by UNIVERSITY OF CALIFORNIA, IRVINE · Jan 26, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how a person’s personality might affect their ability to stick to treatment with specific cancer medications called tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML). The study aims to understand if certain personality traits make it easier or harder for patients to follow their treatment plans, which is important for their health and well-being.

To participate in the study, you need to be at least 18 years old, have been diagnosed with chronic myeloid leukemia in its chronic phase, and currently be treated with one of four specific medications: imatinib, dasatinib, bosutinib, or nilotinib. You must also be a patient at the UCI Chao Family Comprehensive Cancer Center or part of a support group from the CML Buster Foundation. Participants will be asked questions about their personality and treatment adherence, and your responses will help researchers understand how to better support patients with CML. This study is currently looking for new participants, and it’s a chance to contribute to important research in cancer care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years of age or older
• • Diagnosed with chronic myeloid leukemia (CML) and in the chronic phase (CML-CP)
• • Currently being treated with one of four cancer medications - imatinib, dasatinib, bosutinib, or nilotinib
• • A patient at the UCI Chao Family Comprehensive Cancer Center (CFCCC), or
• • A member of a patient support group organized by the CML Buster Foundation
• • Do not meet any of the criteria listed under "Exclusion Requirements"
• Exclusion Criteria:
• • Unable to read and speak English
• • Impaired decisional capacity to consent